Retrieved on:
Thursday, February 1, 2024
Intelligence,
Genetics,
University,
Cardiovascular disease,
Machine learning,
Diagnosis,
FDA,
Drug discovery,
ECG,
Doctor of Philosophy,
Health,
HSCS,
Assistant,
Patent,
Algorithm,
Data science,
Medical device Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
Key Points:
- Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
- “We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences’ Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
- As part of this process, we are actively expanding our Scientific Advisory Board to include industry experts and broaden our outreach.
- I am impressed by their proven track record of innovation and look forward to contributing to HeartSciences at the forefront of this field.”
Retrieved on:
Thursday, January 18, 2024
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
Key Points:
- Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
- At the Annual Meeting which was convened, all items of business were passed, with the exception of Proposal 7, which would effect a reduction of the quorum requirements for future shareholder meetings, as the Company had not received sufficient proxies for approval by the time of the Annual Meeting.
- Each director nominee received a plurality of votes cast at the Annual Meeting.
- The Annual Meeting, with respect to Proposal 7, will reconvene on Thursday, February 15, 2024 at 9:00 a.m. Eastern Time.
Retrieved on:
Wednesday, January 3, 2024
Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to vote ahead of its upcoming 2023 Annual Meeting of Stockholders (“Annual Meeting”) on Wednesday, January 17, 2024 at 9:00 a.m. Eastern (8:00 a.m. Central) Time.
Key Points:
- Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to vote ahead of its upcoming 2023 Annual Meeting of Stockholders (“Annual Meeting”) on Wednesday, January 17, 2024 at 9:00 a.m. Eastern (8:00 a.m. Central) Time.
- All shareholders on record of our outstanding shares of common stock and preferred stock at the close of business on November 20, 2023, are entitled to participate and vote at the Annual Meeting.
- For assistance with voting your shares, please contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at [email protected] .
- HeartSciences asks that all shareholders vote their proxy, no matter how many shares they own.
Retrieved on:
Thursday, December 14, 2023
Shift,
Science,
Global Health,
Classification,
ECG,
FDA,
HSCS,
Electrocardiography,
Patent,
American Medical Association,
Growth,
IPO,
Overalls,
CPT,
Diagnosis,
Cardiovascular disease,
Intelligence,
Algorithm,
De novo,
Medical device Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
Key Points:
- Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
- After the fiscal second quarter's close, we successfully completed a series of actions including an equity raise and debt conversion that remedied the Nasdaq shareholders’ equity deficiency.
- After the close of the second fiscal quarter 2024, the Company raised $9.3 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
- Further, HeartSciences closed a series of license agreements with Mount Sinai which results in Mount Sinai becoming a material shareholder in the Company.
Retrieved on:
Tuesday, December 5, 2023
Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has received confirmation from the FDA to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the more complex De Novo process.
Key Points:
- Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has received confirmation from the FDA to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the more complex De Novo process.
- Andrew Simpson, Chief Executive Officer of HeartSciences, said, "The new FDA product classification for AI-ECG paves the way for a more structured and faster 510(k) process for our MyoVista® device, as well as our industry leading library of AI-ECG algorithms.
- In November, the core lab finished their work on our MyoVista® pivotal study following the conclusion of patient recruitment announced earlier in 2023.
- We remain on track for submission of the MyoVista® to the FDA in the first half of 2024 and a targeted clearance during 2024.”
Retrieved on:
Monday, November 20, 2023
Database,
Cardiology,
ECG,
Division,
Classification,
Mount Sinai Health System,
FDA,
D3M,
Mount Sinai Hospital,
HSCS,
MD,
Doctor of Philosophy,
AI,
Machine learning,
Data science,
Assistant,
Patient,
Diagnosis,
Cardiac electrophysiology,
Cardiovascular disease,
Intelligence,
Algorithm,
Policy,
Medical device The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs.
Key Points:
- The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs.
- The licenses from Icahn Mount Sinai grant rights to multiple patented and unpatented AI-based ECG/EKG algorithms and technologies for the screening and diagnosis of cardiovascular disease.
- The AI cardiovascular algorithms are based on technology developed by Icahn Mount Sinai faculty and licensed by Mount Sinai to HeartSciences.
- The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.
Retrieved on:
Monday, November 13, 2023
In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.
Key Points:
- In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.
- Cardiact is rolling out a newly established heart screening program for the AGSI, which represents sergeants and inspectors of the Garda Síochána national police service of Ireland (“Garda”), to be conducted across Ireland and is due to commence on November 27, 2023.
- Cardiact has also established a new referral pathway directly to cardiology as part of the program.
- Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are delighted that the MyoVista® wavECG™ has been chosen for use in this heart screening program of Irish Garda officers.
Retrieved on:
Tuesday, November 21, 2023
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Thursday, October 19, 2023
HSCS,
FDA,
ECG,
Patent,
Automated ECG interpretation,
Icahn School of Medicine at Mount Sinai,
Data science,
De novo,
Hypertrophic cardiomyopathy,
Database,
Mount Sinai,
Webcast,
Classification,
Algorithm,
AI,
Diagnosis,
Cardiovascular disease,
Medical device Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be hosted on Wednesday, October 25, 2023, at 9:00 AM ET.
Key Points:
- The agreements provide HeartSciences with an industry leading library of AI-based ECG algorithms.
- Terms and requirements related to the agreements will be discussed on the investor call or can be found in HeartSciences’ recently filed S-1 at https://ir.heartsciences.com/sec-filings .
- Andrew Simpson, CEO of HeartSciences, said, "We believe recent announcements fundamentally transform and de-risk HeartSciences.
- Participants may access the conference call live via webcast on the investor relations section of HeartSciences’ websites or via this link .
Retrieved on:
Tuesday, September 26, 2023
HSCS,
Cardiovascular disease,
ECG,
Ministry,
Patent,
Growth,
AI,
Cardiology,
United Arab Emirates,
Pharmaceutical industry,
Medical device,
Medical imaging These new patent awards increase HeartSciences’ patent portfolio to now include 33 international granted or allowed patents and 9 US granted patents covering well over 100 claims.
Key Points:
- These new patent awards increase HeartSciences’ patent portfolio to now include 33 international granted or allowed patents and 9 US granted patents covering well over 100 claims.
- Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “AI is now in daily use in healthcare and is expected to reinvent the ability of an ECG to screen for heart disease.
- We are pleased to further strengthen our extensive intellectual property portfolio as AI is expected to drive significant growth in the ECG market to $25 billion per year by 20321.
- HeartSciences is a leader in AI-based ECG technology being used in everyday clinical practice, and with the recent signing of agreements with Mount Sinai, a top-ranked hospital in cardiology, we expect to significantly expand our ECG cardiovascular disease screening capabilities.”
